Comparative Pharmacology
Head-to-head clinical analysis: EUTRON versus RAUTENSIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EUTRON versus RAUTENSIN.
EUTRON vs RAUTENSIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EUTRON is a combination of hydrochlorothiazide (thiazide diuretic) and pargyline (monoamine oxidase inhibitor, MAOI). Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, reducing plasma volume. Pargyline inhibits MAO, increasing catecholamine levels centrally, leading to antihypertensive effect.
Combination of Rauwolfia serpentina alkaloids (e.g., reserpine) that deplete catecholamines and serotonin from peripheral sympathetic nerve endings and brain, reducing total peripheral resistance and cardiac output.
Oral: 5 mg/2.5 mg (amiodipine/valsartan) once daily; maximum dose 10 mg/320 mg once daily.
1-2 tablets (each containing Rauwolfia serpentina 50 mg and flumethiazide 0.5 mg) orally once daily.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function. In end-stage renal disease (ESRD), half-life may extend to 24-30 hours, requiring dose adjustment.
The terminal elimination half-life of rauwolfia alkaloids is approximately 50-100 hours, with a mean of about 72 hours. This long half-life supports once-daily dosing and leads to slow accumulation and sustained antihypertensive effect.
Renal excretion accounts for approximately 90% of elimination, with 70% as unchanged drug and 20% as metabolites. Biliary/fecal excretion accounts for the remaining 10%.
Rautensin (rauwolfia alkaloids) is primarily excreted via hepatic metabolism and biliary-fecal elimination, with less than 1% excreted unchanged in urine. Renal excretion accounts for approximately 10% of metabolites, while biliary/fecal elimination accounts for approximately 90%.
Category C
Category C
Antihypertensive
Antihypertensive